These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 35856212)

  • 41. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of increased influenza vaccination uptake against readmissions of major adverse cardiac events in the US.
    Peasah SK; Meltzer MI; Vu M; Moulia DL; Bridges CB
    PLoS One; 2019; 14(4):e0213499. PubMed ID: 31034485
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Influenza vaccination in the elderly population in Mexico: economic considerations].
    Gutiérrez JP; Bertozzi SM
    Salud Publica Mex; 2005; 47(3):234-9. PubMed ID: 16104466
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
    Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of inactivated influenza vaccination in children with medical risk conditions in the Netherlands.
    Naber SK; Bruijning-Verhagen PCJL; de Hoog MLA; van Giessen A
    Vaccine; 2020 Apr; 38(17):3387-3396. PubMed ID: 32115297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Cost-effectiveness and affordability of strategy for preventing mother-to-child transmission of hepatitis B in China].
    Lin Y; Zhang SX; Yang PC; Cai YL; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):852-859. PubMed ID: 28738455
    [No Abstract]   [Full Text] [Related]  

  • 47. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.
    Smith KJ; Lee BY; Nowalk MP; Raymund M; Zimmerman RK
    Vaccine; 2010 Nov; 28(48):7620-5. PubMed ID: 20887828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
    Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
    Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis.
    Sandmann FG; van Leeuwen E; Bernard-Stoecklin S; Casado I; Castilla J; Domegan L; Gherasim A; Hooiveld M; Kislaya I; Larrauri A; Levy-Bruhl D; Machado A; Marques DFP; Martínez-Baz I; Mazagatos C; McMenamin J; Meijer A; Murray JLK; Nunes B; O'Donnell J; Reynolds A; Thorrington D; Pebody R; Baguelin M
    Vaccine; 2022 Feb; 40(9):1306-1315. PubMed ID: 35109968
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Optimization of Elderly Influenza and Pneumococcal Immunization Programs in Beijing, China Using Health Economic Evaluations: A Modeling Study.
    Pi Z; Aoyagi K; Arima K; Wu X; Ye Z; Jiang Y
    Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680005
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
    Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modelling the optimal target age group for seasonal influenza vaccination in Japan.
    Tsuzuki S; Baguelin M; Pebody R; van Leeuwen E
    Vaccine; 2020 Jan; 38(4):752-762. PubMed ID: 31735503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Bellier L; Petitjean A; Sarazu T; Tresierra J; Lopez JG
    Vaccine; 2021 Jul; 39(30):4144-4152. PubMed ID: 34130885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel.
    Yamin D; Balicer RD; Galvani AP
    Vaccine; 2014 Jul; 32(33):4198-205. PubMed ID: 24930716
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of seasonal influenza vaccination in pregnant women, healthcare workers and adults >= 60 years of age in Lao People's Democratic Republic.
    Ortega-Sanchez IR; Mott JA; Kittikraisak W; Khanthamaly V; McCarron M; Keokhonenang S; Ounaphom P; Pathammavong C; Phounphenghack K; Sayamoungkhoun P; Chanthavilay P; Bresee J; Tengbriacheu C
    Vaccine; 2021 Dec; 39(52):7633-7645. PubMed ID: 34802790
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
    García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
    Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost effectiveness of a practice-based intervention to improve vaccination rates in adults less than 65-years-old.
    Smith KJ; Nowalk MP; Lin CJ; Zimmerman RK
    Hum Vaccin Immunother; 2017 Oct; 13(10):2207-2212. PubMed ID: 28829719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness analysis of hepatitis E vaccination strategies among patients with chronic hepatitis B in China.
    Cui T; Zhang X; Wang Q; Yue N; Bao C; Jiang R; Xu S; Yuan Z; Qian Y; Chen L; Hang H; Zhang Z; Sun H; Jin H
    Hepatol Res; 2024 Feb; 54(2):142-150. PubMed ID: 37706554
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
    Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of increasing vaccination in high-risk adults aged 18-64 Years: a model-based decision analysis.
    Wateska AR; Nowalk MP; Zimmerman RK; Smith KJ; Lin CJ
    BMC Infect Dis; 2018 Jan; 18(1):52. PubMed ID: 29370768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.